An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Item

http://www.wikidata.org/entity/Q34881233

Q34881233

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Neuroplasticity and the next wave of antidepressant strategies Ketamine and other glutamate receptor modulators for depression in adults A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder Rapid antidepressant effects: moving right along Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review Zinc in the Glutamatergic Theory of Depression Novel NMDA receptor modulators: an update Review of pharmacological treatment in mood disorders and future directions for drug development.Antidepressant actions of ketamine: from molecular mechanisms to clinical practice NMDA receptor modulators: an updated patent review (2013-2014)Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Ketamine for treatment-resistant unipolar depression: current evidence Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists A brief history of the development of antidepressant drugs: from monoamines to glutamate Essential role of GluD1 in dendritic spine development and GluN2B to GluN2A NMDAR subunit switch in the cortex and hippocampus reveals ability of GluN2B inhibition in correcting hyperconnectivity.Glutamate receptor ion channels: structure, regulation, and function The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development Innovative solutions to novel drug development in mental health mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Chronic antidepressant treatment impairs the acquisition of fear extinction.Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B.Acute D-serine treatment produces antidepressant-like effects in rodents Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.Experimental medication treatment approaches for depression.From synapse to nucleus: novel targets for treating depression.

P2860

Q21129276-7A55AB88-DB81-4949-A56E-6F0003E4211F Q21129480-6C0E5913-761D-4275-A007-4ACFAA971671 Q24186746-DEA7FEE5-7446-41EA-AE26-C153346BACC2 Q24602988-48FCE52F-3F12-4850-8C30-93DF2A45AF4E Q24614410-A0034508-326B-4FA2-9069-14F4B49818A6 Q24629780-BFAECE90-C46B-4639-8B3D-A78FD1F37CC0 Q24630153-A5B5B8FA-7DF9-4512-BB84-E951CD3D6837 Q24632936-01358C95-A570-4A4C-8EB2-FAF5F3F4F742 Q26750021-A8C119DC-7ED9-4FDA-9CEB-9F395AD1DDED Q26773084-32D28CBF-EC5D-4376-A8EB-9AA9A9B2BEF4 Q26778251-BA567895-9F45-40CE-831C-D10C35CD026A Q26782274-47ADD0D9-ED19-498A-BEFE-84D9798B7477 Q26782993-364D1FFE-3039-4340-8C88-B748F524D5D1 Q26786214-381808AC-A9B8-47B6-A25C-C0C1C4546DD1 Q26849614-4F625993-02F9-408C-A125-E835BFA89DAA Q26853509-69CC01AE-A847-409D-9F55-AE005A686601 Q26995879-06DB1ED9-F8CD-4328-8400-83FCA2A558D5 Q26997407-557056CA-6480-4029-B3CC-718086ED886B Q27004490-17DDEAFB-23AE-4A7A-9111-972CD1E57E24 Q27004508-D574B476-0939-4C24-8F24-EB2BE2129096 Q27024227-F1AAE0A2-34C0-458C-8B5A-F09823FFE9AE Q27025974-7F7447C3-DC06-413B-B280-945E6DF227CB Q27028050-03B31059-93ED-4EAA-94DA-EACD8654719D Q27305133-0C914A0A-92E5-4E32-9C11-6E50064A5DA8 Q28290774-3D797F76-665B-469D-952F-D2A08F8A2883 Q28551131-6D9656AB-86A1-46BE-9E84-49488CDB6937 Q28677399-99590E3F-BE04-4F9F-947F-6CD13611F5AD Q29618120-7D93F849-FC54-4594-A59A-37570608B0E9 Q30437449-A7B810DA-F34D-4227-BC34-24EABF3C18BA Q30495175-15B7B5D0-B3C4-41B7-A623-FA8CD4907CFD Q30505292-DEA478B2-FBC9-4617-86BF-8AB400B82DF3 Q30508512-8F7BF2EC-FB52-4219-A3B4-88483585A8CF Q30572014-7B68B9E4-5900-4329-A2D5-F8417BC9080D Q30595767-02FB23C3-C848-4090-8004-79A40EE10497 Q30711088-92A7A00F-7A07-4B76-AE42-3EE6EBB695F3 Q30830257-DD45E26E-5415-4A32-B037-378D92251E4D Q30841490-040B1DDD-D959-4B2B-8B12-4266E81528FD Q33536202-2B11163C-7AF2-4AE8-86E1-8D4405908B86 Q33635577-551CBD17-E66D-4C14-8337-5C8FE158615F Q33653177-12F2C93A-F076-4CAF-9DBF-F0BD6109FF8A

P2860

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Item

http://www.wikidata.org/entity/Q34881233

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu